Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.8% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price fell 4.8% on Monday . The stock traded as low as $6.44 and last traded at $6.55. 4,844,177 shares changed hands during mid-day trading, a decline of 68% from the average session volume of 14,941,520 shares. The stock had previously closed at $6.88.

Analyst Ratings Changes

Several brokerages have commented on RXRX. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.75.

Recursion Pharmaceuticals Stock Up 1.6 %

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -4.20 and a beta of 0.85. The stock’s fifty day simple moving average is $6.93 and its two-hundred day simple moving average is $6.97.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the company posted ($0.43) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at approximately $3,288,380.78. This trade represents a 1.14 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the completion of the sale, the director now directly owns 7,077,560 shares of the company’s stock, valued at $47,561,203.20. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,894 shares of company stock valued at $317,139 in the last three months. 15.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals during the third quarter valued at about $25,000. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $26,000. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares during the last quarter. Finally, Amalgamated Bank raised its position in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.